Vignali, Paolo D. A.
DePeaux, Kristin http://orcid.org/0000-0001-8460-727X
Watson, McLane J.
Ye, Chenxian http://orcid.org/0000-0003-2700-3271
Ford, B. Rhodes
Lontos, Konstantinos http://orcid.org/0000-0003-0216-3818
McGaa, Nicole K.
Scharping, Nicole E. http://orcid.org/0000-0001-9373-4617
Menk, Ashley V.
Robson, Simon C. http://orcid.org/0000-0001-6374-0194
Poholek, Amanda C. http://orcid.org/0000-0002-5587-8940
Rivadeneira, Dayana B.
Delgoffe, Greg M. http://orcid.org/0000-0002-2957-8135
Article History
Received: 27 January 2022
Accepted: 3 November 2022
First Online: 21 December 2022
Competing interests
: A.V.M. is currently an employee of Novasenta. G.M.D. declares competing financial interests and has submitted patents targeting exhausted T cells that are licensed or pending and is entitled to a share in net income generated from licensing of these patent rights for commercial development. G.M.D. consults for and/or is on the scientific advisory board of BlueSphere Bio, Century Therapeutics, Nanna Therapeutics, Novasenta, Pieris Pharmaceuticals and Western Oncolytics/Kalivir; has grants from bluebird bio, Novasenta, Pfizer, Pieris Pharmaceuticals, TCR2 and Western Oncolytics/Kalivir. G.M.D. owns stock in Novasenta, BlueSphere Bio and RemplirBio. The other authors declare no competing interests.